IO Frontiers World 2019


Yijia Li

Dr Yijia Li

Director, Shunxi Regenerative Medicine, Yunnan Province Stem Cell Bank
Dr. Yijia Li has a bachelor degree of biology from Tsinghua University and double degree of Economics and Management from Peking University. After his Ph.D. at Florey Institute of Neuroscience and Mental Health, he joined Shunxi-Monash University Joint Lab, participated and facilitated several translational projects with Monash University, University of Melbourne, RMIT, CSIRO, ARC and NHMRC. In 2015, he was appointed as the director of Yunnan Province Stem Cell Bank (YSCB) and Yunnan Shunxi Stem Cell and Regenerative Medicine Research Center (SSRC). YSCB and SSRC has around 1600 m2 GMP lab space can hold up to 400,000 stem cell samples and can do 200 Human Whole Exome Sequencing every week. The aim of YSCB and SSRC is to develop stem cell storage and expend method (including hESC, HSC, MSC, PSC and ASC), carry out genome research on stem cell and cancer, and began clinical trails on stem cell treatments for cancer, such as DC-CIK, CAR-T and other technics. He is leading several projects on stem cell in China and Australia with government and private fund up to nearly 6 million USD and translated several books into Chinese including 5th Edition of NetCord-FACT Cord Blood Accreditation Manual. He would like to set up international collaborations to help translate basic stem cell research into clinical use to provide safe and effective treatments.
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy